That said, however, a team of scientists at Kings College London believe they've uncovered one rather common indicator of Parkinson's, which they say can emerge during very early stages.

The drug will now progress to pivotal Phase III trials after demonstrating trends towards a disease-modifying impact.

As much as 31% of the world’s population has metabolic syndrome. Past research shows that metabolic syndrome can lead to diseases like Parkinson’s disease. A new study provides further evidence of a ...

Gut health has been linked to a common neurological disorder in a new study. Those who have sustained damage to the upper lining of their gastrointestinal (GI) tract are 76% more likely to develop ...

With a flurry of startup activity, tech to monitor the symptoms of Parkinson’s disease is building momentum in care for the ...

The world's largest-ever clinical trial of treatments to slow or stop the progression of Parkinson's disease has launched, led by researchers at UCL and Newcastle University.

ON™, continuous monitoring of Parkinson's symptoms can enhance treatment efficacy and significantly lower healthcare costs ...